Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 385

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 385
---
ise Genômica S.A., Diagnósticos da América S.A.; Igenomix S.L.; Nimgenetics Genómica Y Medicina, S.L.; Color Health, Inc.; Bitgenia Brasil Ltda.; Biomakers S.A.; Argenetics Semillas S.A.; Argenomics S.A.; Genda S.A.; Genos S.A.; Biocodices S.A.; Diagnóstico Maipú por Imágenes S.A.; Viome Life Sciences, Inc; Zoe Limited; 23andMe, Inc.; Ambry Genetics Corporation, a subsidiary of Realm IDx, Inc.; Athena Diagnostics, Inc. and Blueprint Genetics, subsidiaries of Quest Diagnostics Incorporated; Baylor -MiracaGenetics Laboratories LLC; Centogene AG; Connective Tissue Gene Test LLC, a subsidiary of Health Network Laboratories, L.P.; Cooper Surgical, Inc.; Emory Genetics Laboratory, a subsidiary of Eurofins Scientific; Exact Sciences Corporation; Foundation Medicine, Inc., a subsidiary of Roche Holding AG; Freenome Holding, Inc.; Fulgent Genetics, Inc.; GeneDx Holdings Corp; Guardant Health, Inc.; Integrated Genetics, Sequenom Inc., Correlagen Diagnostics, Inc., and MNG Laboratories, subsidiaries of Laboratory Corporation of America Holdings; Myriad Genetics, Inc.; Natera, Inc.; Tempus Labs, Inc., as well as other commercial and academic laboratories. Further, we face competition from new entrants in the market for genetic screening, including informatics and analysis pipeline developers as well as focused, integrated providers of genetic tools and services for health and wellness, including Illumina, which is also one of our suppliers. In addition to the companies that currently offer traditional genetic testing services and research centers, other established and emerging healthcare, information technology and service companies may commercialize competitive products including informatics, analysis, integrated genetic tools and services for health and wellness. We believe that we are uniquely positioned to compete based on several key competitive factors: • Geographic focus on Latin America: our operations are focused on Latin America, leveraging our extensive knowledge of the local regulatory environment, languages, and cultural context. We have developed 9+ years of operational expertise and a strong network of partner laboratories across Latin America, four of which are investors in OmnigenicsAI. This network facilitates rapid and efficient market entry, providing regional labs with localized end -to -endsolutions adapted to market needs without requiring additional investments from partners. • Comprehensive Insights, Precision and Actionable Results